Eric represents clients in the pharmaceutical and life sciences industries in patent and commercial litigation matters. He has extensive experience handling complex patent infringement litigation arising under the Hatch-Waxman Act and the Biologics Price Competition and Innovation Act. Eric also conducts due diligence investigations with regards to patent validity and infringement.
Prior to joining Fenwick, Eric was an associate in the intellectual property group of a leading international law firm.
- Representing a diagnostics company in the Federal Circuit concerning a patent dispute related to an innovative myasthenia gravis diagnostic method.
- Representing a pharmaceutical company in the Eastern District of Virginia and the Federal Circuit in a declaratory judgment action concerning humanized antibody technology. The district court held the client’s product to be non-infringing and the Federal Circuit affirmed.
- Representing pharmaceutical companies in Hatch-Waxman litigation in the District of Delaware and on-appeal in the Federal Circuit.
- Representing a pharmaceutical company, as amicus curiae, in a Federal Circuit appeal concerning the patent eligibility and validity of antibody technology.
Education & Admissions
J.D., University of Michigan Law School
M.S., Chemistry, University of Michigan
B.S., Biochemistry, Daemen College
Admitted to practice in New York
Admitted to practice before the U.S. Court of Appeals for the Federal Circuit, and the Southern and Eastern Districts of New York